Drugs in Development
DT-310
Indication(s): Breast, Bladder, Pancreatic, Prostate, and Lung Cancer
Patent: US Pending
A small MW compound found in diversity chemical library screen. Testing currently underway has selective kill against suppressed breast, bladder, pancreatic, prostate, and lung cancer cells in culture. Suppressed tumor cell kill has also been verified in tumor-bearing mouse bladder and breast models. Proof of anti-metastasis has also been verified in orthotopically implanted MDA-MB-435 tumor cells. Eight-week initial TOX studies show no overt toxicity in two different rodent models.
DT-320
Indication(s): Breast, Bladder, and Pancreatic Cancer
Patent: US Pending
A small MW compound found in diversity chemical library screen. Testing currently underway has selective kill against suppressed breast, bladder, and pancreatic cancer cells in culture. Suppressed tumor cell kill has also been verified in a tumor-bearing mouse bladder model. Eight-week initial TOX studies show no overt toxicity.
DT-330
Indication(s): Breast, Bladder, Pancreatic, and Colon Cancer
Patent: US Pending
A small MW compound found in diversity chemical library screen. Testing currently underway has selective kill against suppressed breast, bladder, pancreatic, and colon cancer cells in culture. Suppressed tumor cell kill has also been verified in tumor-bearing mouse bladder and breast models. Preliminary studies suggest that this compound may induce a form of cell death called apoptosis in suppressed cancer cells. Eight-week initial TOX studies show no overt toxicity in two different rodent models.
